Mariner’s Palvella Therapeutics PVLA Stock Holding History

Mariner’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$551K	Sell	4,420 -7,195	-62%	-$751K	﹤0.01%	2424
2025 Q4	$1.22M	Sell	11,615 -9,107	-44%	-$777K	﹤0.01%	1813
2025 Q3	$1.3M	Buy	+20,722	New	+$924K	﹤0.01%	1718
2019 Q4	–	Sell	-813	Closed	-$222K	–	727
2019 Q3	$222K	Hold	813	–	–	﹤0.01%	670
2019 Q2	$306K	Hold	813	–	–	﹤0.01%	878
2019 Q1	$218K	Hold	813	–	–	﹤0.01%	935
2018 Q4	$173K	Hold	813	–	–	﹤0.01%	784
2018 Q3	$364K	Hold	813	–	–	0.01%	614
2018 Q2	$330K	Hold	813	–	–	0.01%	623
2018 Q1	$443K	Hold	813	–	–	0.02%	456
2017 Q4	$491K	Hold	813	–	–	0.02%	393
2017 Q3	$374K	Buy	+813	New	+$347K	0.02%	388

Other funds holding PVLA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Mariner's PVLA Position: Q1 2026 in Review

Mariner reduced its Palvella Therapeutics (PVLA) stake by 62% in Q1 2026, selling an estimated $751K and leaving 4,420 shares worth $551K. The position accounts for ﹤0.01% of the portfolio, ranked #2424.

Mariner first reported a position in PVLA in Q3 2017 and has held it in 12 quarters since. The position peaked at $1.3M in Q3 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

Mariner held 4,420 shares of Palvella Therapeutics worth $551K as of Q1 2026.
Mariner sold 7,195 Palvella Therapeutics shares in Q1 2026, an estimated $751K.
Palvella Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2424 holding.
Mariner first reported a position in Palvella Therapeutics in Q3 2017 and has held it in 12 quarters since.
Mariner's Palvella Therapeutics position peaked at $1.3M in Q3 2025.
180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.